BioSpace News Archive

New international research in the September 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network adds important knowledge about how immunotherapy-related adverse events (irAEs) can impact more than one organ in a single patient.

Charles River Laboratories International, Inc. announced that it will virtually present at three upcoming investor conferences, including

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that 3 additional patients have completed the 48-week Phase I/II study.

Progression to Phase 3 clinical trials represents significant acceleration of atopic dermatitis development program Previously reported data demonstrated evidence that roflumilast cream provided symptomatic improvement and a favorable tolerability profile Roflumilast cream is a novel PDE4 inhibitor being developed as a once-daily topical cream for atopic dermatitis and psoriasis WESTLAKE VILLAGE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a

EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2), (the “Company” or “EXM”), an emerging bio-sciences company specializing in the production of unique cannabinoid formulations, is pleased to announce its success in securing COVID-19 R&D-focused grant from the European Union and the Portuguese Government, detailing a landmark event for the Company.

Orbis International announces the appointment of Derek Hodkey as the organization’s new CEO and President, with immediate effect, following the retirement of Bob Ranck, who led Orbis for over four years.

Gene therapy is a massive and swiftly expanding field that could hold promising cures and treatments for several diseases and genetic problems.

Celularity announced today that the first patient was dosed in a Phase I/II study of human placental hematopoietic stem cell derived NK cells (CYNK-001) for the treatment of adults with COVID-19 as part of a national clinical trial.

Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth enabled, virtualized outpatient healthcare treatment company, today announced that it has closed the full exercise of the underwriters’ over-allotment option regarding its previously announced underwritten public offering of 9.50% Series A Cumulative Perpetual Preferred Stock (the “Series A Preferred Stock“)

PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, announced the appointments of Laurie Stelzer to the Board of Directors as Audit Committee chair, and Robert Ticktin as General Counsel.